摘要
目的探讨维生素D与多发性硬化防治的相关性,为疾病治疗提供新思路、新方向。方法选取梅州市人民医院2016年1月至2018年9月收治的25例多发性硬化患者作为研究对象,均为复发-缓解型多发性硬化患者,依照治疗方法进行分组,其中10例行单纯糖皮质激素治疗的患者分为对照组,另外15例行糖皮质激素联合维生素D治疗的患者分为观察组。随访2年,比较两组患者治疗前后Kurtzke扩展残疾状况量表(EDSS)评分及干扰素-γ(IFN-γ)、白细胞介素-10(IL-10)水平,观察不良反应和复发情况。结果治疗3个月、6个月、12个月、24个月,观察组EDSS评分明显低于对照组,差异有统计学意义(P<0.05)。治疗2周、随访4周,两组IFN-γ、IL-10水平降低,且观察组改善幅度明显高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率与复发率明显低于对照组,差异有统计学意义(P<0.05)。结论维生素D联合糖皮质激素用于多发性硬化的防治作用明显,能够改善患者的神经功能,调节免疫状态。
Objective To analyze the correlation between vitamin D and the prevention and treatment of multiple sclerosis, and to provide new ideas and directions for disease treatment. Methods A total of 25 subjects in this study, all patients with relapsing-remitting multiple sclerosis, were grouped according to the treatment method. Among them, 10 patients treated with glucocorticoid alone were listed as the control group, and the other 15 were treated with glucocorticoids. Patients treated with hormone combined with vitamin D were classified as the treatment group, and all study subjects were selected from January 2016 to September 2018. Follow up for 2 years, compare the EDSS scores of patients before and after treatment, count the levels of IFN-r and IL-10 before and after treatment, and observe the adverse reactions and recurrence. Results After treatment for 3 months, 6 months, 12 months, and 24 months, the EDSS score of the observation group was significantly lower than that of the control group, and the difference was statistically significant(P<0.05). After 2 weeks of treatment and 4 weeks of follow-up, the levels of IFN-γ and IL-10 in the 2 groups decreased, and the improvement in the observation group was significantly higher than that in the control group. The difference was statistically significant(P<0.05). The incidence and recurrence rate of adverse reactions in the observation group were significantly lower than those in the control group, and the difference was statistically significant(P<0.05). Conclusion Vitamin D combined with glucocorticoid has a good effect on multiple sclerosis, can enhance the patient’s anti-inflammatory ability, regulate immune function.
作者
李晴
LI Qing(Meizhou People’s Hospital,Meizhou 514000,China)
出处
《中国药物经济学》
2020年第11期113-115,118,共4页
China Journal of Pharmaceutical Economics
基金
2018年梅州市医药卫生科研立项课题(2018-B-28)。
